GlaxoSmithKline Share Price (GSK)

0.00 0.00 (0.00%) delayed: 1:33AM GMT
Bid price 1,314.00 Open price 0.00
Ask price 1,314.50 Prev close 1,314.50
High price 0.00 Spread 0.00%
Low price 0.00 Volume 0

Register now for FREE live GlaxoSmithKline share prices, GlaxoSmithKline stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get GlaxoSmithKline Level 2 Data, indepth research tools and investor commentary for GlaxoSmithKline (GSK) and other London Stock Exchange equities.

GlaxoSmithKline Share Price Chart

Advanced Charts >>

Register now for FREE GlaxoSmithKline share price charts

GlaxoSmithKline Share Price Information

Name GlaxoSmithKline Epic GSK
Sector Pharmaceuticals & Biotechnology ISIN GB0009252882
Activites GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Around 35,000 employees work at 82 manufacturing sites in 37 countries and over 15,000 are in R&D. GSK R&D is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.8bn/$5bn. Index FTSE 100

GlaxoSmithKline Key Numbers

Latest Share Price (p) 0.00 Net Gearing (%) 83.31
Market Capitalisation (£m) 64,090.58 Gross Gearing (%) 91.60
Shares in issue (m) 4,918.69 Debt Ratio 87.62
P/E Ratio 69.31 Debt-to-Equity Ratio 0.65
Total dividends per share (p) 80.00 Assets / Equity Ratio 11.90
Dividend Yield (%) 6.14 Price to book value 12.91
Dividend cover (x) 0.24 ROCE (%) 4.84
Earning per share (p) 18.80 EPS Growth (%) -89.21
52 week high / low 1,724.50 / 1,270.00 DPS Growth (%) 0.00

GlaxoSmithKline Director Deals

Dec.Date Type Director Pos No. of Shares
01/12/2017 BUY Simon Dingemans FD 238
25/10/2017 BUY Sir Roy Anderson NED 473
25/10/2017 BUY Sir Philip Hampton CH 2,882
25/10/2017 BUY Urs Rohner NED 473
25/10/2017 BUY Manvinder Banga NED 1,894

More GlaxoSmithKline Director Deals >>

GlaxoSmithKline Company News

16:50 12/12/2017

Director/PDMR Shareholding

RNS Number : 1409Z GlaxoSmithKline PLC 12 December 2017   GlaxoSmithKline plc   (the   ' Company ')   Transaction notification   1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley...

16:16 12/12/2017

GSK gains US approval for Nucala to treat EGPA

RNS Number : 1354Z GlaxoSmithKline PLC 12 December 2017   Issued: Tuesday 12 December 2017, London UK     GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US   First...

09:09 12/12/2017

GSK presents promising new data at ASH

GlaxoSmithKline has presented promising new data from the dose expansion phase of the DREAMM-1 study of GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate. In this study of heavily pre-treated multiple myeloma patients (n=35), GSK2857916 monotherapy...

More GlaxoSmithKline Company News >>

Register now for FREE GlaxoSmithKline company news

GlaxoSmithKline Share Price Discussions

more than 1 year ago

Glaxo trading near low (GSK)

there seems to be some heavy resistance around these level with a lot of potential upside.

more than 1 year ago

Traders Thread - Friday 13th February (GSK)

UK PreMarket Futures FTSE +8 DAX Unch DOW +26 S&P +2 Nasdaq +5 1 Day 2 Day...

more than 1 year ago

Traders Thread - Friday 13th February (GSK)

UK PreMarket Futures FTSE +8 DAX Unch DOW +26 S&P +2 Nasdaq +5 1 Day 2 Day...

Register now for FREE GlaxoSmithKline share price discussions